Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders. If you currently own Lifecore stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about.

Business Wire • Dec 7, 2025

Lifecore Biomedical to Participate in Upcoming Investor Conferences

CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore's participation are as follows:

GlobeNewsWire • Nov 11, 2025

Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript

Lifecore Biomedical, Inc. ( LFCR ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Josephs - President, CEO & Director Ryan Lake - Executive VP & CFO Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Hannah Hefley - Stephens Inc., Research Division Lucas Baranowski - KeyBanc Capital Markets Inc., Research Division Christine Rains - William Blair & Company L.L.C., Research Division Presentation Stephanie Diaz Vida Strategic Partners, Inc. Good afternoon, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter 2025 Earnings results for the 3 months ended September 30, 2025.

Seeking Alpha • Nov 7, 2025

Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update

--  Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025 , Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced its financial results for the three months ended September 30, 2025.

GlobeNewsWire • Nov 6, 2025

Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates

Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.53 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025

CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close.

GlobeNewsWire • Oct 30, 2025

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product

GlobeNewsWire • Oct 29, 2025

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S.

GlobeNewsWire • Oct 28, 2025

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company's activities at these events are as follows:

GlobeNewsWire • Oct 13, 2025

LIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  LifeCore between October 7, 2020, and March 19, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

GlobeNewsWire • Sep 27, 2025